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Purpose. Critical illnesses are assessed according to the sequential organ failure assessment (SOFA) and acute physiology and
chronic health evaluation (APACHE) II. Circulating ischemia-modified albumin (IMA) is a biomarker generated under ischemic
and oxidative conditions and may reflect disease severity in preoperative patients. This study investigated the correlations of IMA
with SOFA and APACHE II scores in inpatients admitted for colorectal surgery.Methods. We examined 27 patients with advanced
colorectal cancers (mean age 69 years, men/women = 15/12). Correlations between SOFA and APACHE II scores in addition to
preoperative serum IMA and C-reactive protein (CRP) levels were analyzed. Results. The mean IMA level was 0.5 AU, and the
median CRP level was 0.6mg/dL. Median scores for SOFA and APACHE II were 2 and 12 points, respectively. Significant positive
correlations between IMA and SOFA (𝑟 = 0.45, 𝑃 < 0.05) and IMA and APACHE II (𝑟 = 0.45, 𝑃 < 0.05) were identified which
remained significant in confounder-adjusted analyses. In contrast, weak correlations were observed between CRP and the SOFA
and APACHE II scores. Conclusions. The positive correlations between IMA and both SOFA and APACHE II scores suggest that
serum IMA measurements reflect the severity of systemic failure in patients admitted for colorectal surgery in the preoperative
phase.
1. Introduction
Albumin has a binding site of transitional metal ions,
including cobalt and copper, on its N-terminal region [1].
Ischemic and oxidative stress modifies this terminal peptide
irreversibly to a dysfunctional form, known as ischemia-
modified albumin (IMA) [2, 3]. IMA has been studied as
a surrogate of cardiac ischemia and as a marker related to
critical pathologies, including cancers as well [4–9].
In critically ill patients, assessment based on disease
severity is crucial for providing suitable treatments and
improving outcomes; therefore, several scoring systems have
been developed. The sequential organ failure assessment
(SOFA) [10] and the acute physiology and chronic health
evaluation (APACHE) II [11, 12] are available as scoring
systems of disease conditions of patients undergoing surgical
treatment and/or intensive care. The clinical implications of
these scoring systems have been confirmed, though there
are some problematic aspects (e.g., complexity of scoring),
and the scoring systems are not perfect in patient assessment
[13]. Thus, research on patient assessment using these scores
should be further explored.
Colorectal cancer is common in modern societies, and
the management of colorectal cancer is crucial [14]. Col-
orectal tumors have increased levels of different markers of
oxidative stress, such as increased levels of reactive oxygen
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species and nitric oxide [15, 16]. A prior study reported that
the levels of serum IMAand the number of diseased coronary
arteries were positively correlated [17].The increase of serum
IMA levels was associated with the elongation of the seizure
period [18]. Thus, the degree of oxidative stress is thought to
be associated with disease severity. To date, the relationship
between the IMA and the degree of severity in patients
with colon cancers is unknown. Therefore, the current study
investigated the correlation of IMAwith SOFA and APACHE
II scores in patients admitted for colorectal surgery.
2. Methods
A total of 27 patients were consecutively enrolled into the
study. The study was conducted in accordance with the
Declaration of Helsinki (1964) [19] and approved by the
Ethics Committee of Jichi Medical University. The study
was conducted at our university hospital in 2012. Included
were patients for whom surgery was indicated for advanced
colorectal cancer as well as colonic obstruction and peri-
tonitis due to cancer. Informed consent was obtained in the
presurgical phase.
For each patient, esophageal temperature was recorded.
Blood pressure and heart rate were determined using an
automated sphygmomanometer (BSM-6701; Nihon Kohden
Corp., Tokyo, Japan). The respiratory rate and the Glasgow
coma scale score [20] were evaluated before induction of
anesthesia. Clinical conditions, such as the use of inotropes
and underlying diseases (i.e., chronic organ insufficiency,
immunodeficiency, diabetes mellitus, and ischemic heart dis-
ease), were based on information obtained from the patients’
medical charts.
Arterial blood gas analysis (electrode method) was per-
formed to determine pH, arterial oxygen partial pressure
(PaO
2
), and alveolar-arterial oxygen difference (A-aDO
2
).
Hematocrit, leukocyte counts, and platelet counts were
determined by an autoanalyzer (Beckman Coulter, LH800
system, Tokyo, Japan). Plasma sodium and potassium levels
were determined with a selective electrode method. Serum
bilirubin levels were determined with an enzymatic method.
These were all measured at our single, central hospital
laboratory. Blood samples were measured at 3 days before
operations in patients with the elective surgery, whereas all
measurements were performed at least 1 hour before the
emergency operation started.
Serum CRP levels were determined with an enzyme-
linked immunosorbent assay (Eiken Chemical Co. Ltd.,
Tokyo, Japan). Serum IMA levels were determined with
cobalt2+-binding reduction in our laboratory, as published
previously [4]. Briefly, a 100 𝜇L serum sample was added to
a 25 𝜇L solution of 1 g/L cobalt chloride. Then, dithiothreitol
(25 𝜇L of a 1.5 g/L solution) was added. The absorbance of
the mixture was recorded at 470 nm, and the IMA level
was expressed as the delta absorbance in arbitrary units
between the individual control (without dithiothreitol) and
the reaction sample.
The SOFA score was developed to evaluate the degree of
organ dysfunction [10]. The SOFA scoring scheme assigns
1 to 4 points to each of the levels of dysfunction of six
organs (respiratory, circulatory, renal, hematological, hepatic,
and central nervous systems). The following components are
included: PaO
2
/FiO
2
, mean blood pressure, serum creatinine
or daily total urine volume, platelet count, serum bilirubin,
and Glasgow coma scale score. A score of 0 to 24 points is
assigned, and a higher score is associated with higher severity
[10].
The APACHE II score is evaluated based on the initial
score of 12 components, with a distribution of 0 to 71 points.
The severity is higher when the score is higher [11]. The
evaluation is composed of three parts, including physiologic
scores ranging from 0 to 60 points, age scores ranging from
0 to 6 points, and comorbid disease scores ranging from 0
to 5 points. The physiologic parameters include body tem-
perature, mean blood pressure, heart rate, respiratory rate,
PaO
2
, A-aDO
2
, pH, serum sodium, serum potassium, serum
creatinine, hematocrit, white blood cell count, and Glasgow
coma scale score. In general, the APACHE II score is used
in patients treated in the intensive care unit (ICU). However,
a previous report has shown the usefulness of preoperative
application of the score to evaluate postoperative morbidity
and death among patients undergoing elective surgery [21].
Evaluating a single SOFA score alonemay be of dubious value;
therefore, in the current study, the authors decided to use
the preoperative APACHE II score in addition to the SOFA
score, in order to guarantee the disease severity of the studied
patients.
Data are expressed as means ± standard deviation or
medians with interquartile ranges. The correlations between
the IMA or CRP levels and the other variables were examined
using Pearson’s correlation test. When the correlation test
was significant, a subsequent multiple regression analysis,
adjusted for confounders such as age and sex (Model 1) as
well as age, sex, and the presence of diabetes mellitus and
ischemic heart disease (Model 2), was also used to examine
the correlations between the IMA and CRP levels and the
other variables. All variables with skewed distributions were
log-transformed for all analyses. The data were analyzed
using SPSS 17.0 software (SPSS Inc., Chicago, IL, USA). A 𝑃
value < 0.05 was considered significant.
3. Results
The clinical data are shown in Table 1. The study population
included eight patients with diabetes mellitus and one patient
with a previous history of ischemic heart disease. There
was a significant positive correlation between the SOFA and
APACHE II scores (𝑟 = 0.54, 𝑃 < 0.01). As shown in
Table 2 and Figures 1 and 2, there were significant positive
correlations between IMA and SOFA (𝑟 = 0.45, 𝑃 = 0.02)
and between IMA and APACHE II (𝑟 = 0.45, 𝑃 = 0.02).
The positive correlation between IMA and SOFA remained
significant (Model 1: 𝛽 = 0.48, 𝑃 = 0.02; Model 2: 𝛽 = 0.50,
𝑃 = 0.02) in the confounder-adjusted analyses. The positive
correlation between IMA and APACHE II also remained
significant (Model 1: 𝛽 = 0.44, 𝑃 = 0.02; Model 2: 𝛽 = 0.53,
𝑃 = 0.02) in the confounder-adjusted analyses.
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Table 1: Clinical data of the studied patients.
Variable Levels
Age, years 69 ± 12
Men : women 15 : 12
IMA, AU 0.53 ± 0.10
CRP, mg/dL 0.6(0.1–5.5)
SOFA, points 2 (0–3)
APACHE II, points 12 (7–16)
Body temperature, ∘C 36.6 ± 0.7
Mean blood pressure, mmHg 90 ± 23
Hypotension or use of an inotrope, 𝑛 6 (22%)
Heart rate, bpm 86 ± 24
Respiratory rate, breaths/min 20 ± 8
A-aDO2 (FiO2 > 50%) or PaO2 (FiO2 < 50%), mmHg 375 ± 121
pH 7.4 ± 0.9
Plasma sodium, mmol/L 139 ± 4
Plasma potassium, mmol/L 4.3 ± 0.8
Serum creatinine, mol/L 80 (53–114)
Acute renal failure, 𝑛 2 (0.7%)
Hematocrit, % 34.8 ± 6.5
Leukocytes, ×109/L 6.7(4.7–12.3)
Platelets, ×109/L 239 ± 86
Bilirubin, mol/L 12 (9–14)
Glasgow coma scale, points 14.4 ± 1.6
Organ insufficiency or immunodeficiency, 𝑛 13 (48%)
IMA: ischemia-modified albumin; CRP: C-reactive protein; SOFA: sequen-
tial organ failure assessment; APACHE: acute physiology and chronic health
evaluation.
Data are expressed as means ± standard deviations, medians (interquartile
ranges), or patient numbers.
Table 2: Correlation coefficients of IMAorCRPwith other variables
related to APACHE II or SOFA.
Variables IMA CRP
Age, years 0.05 (0.79) 0.18 (0.37)
Men −0.03 (0.90) 0.01 (0.98)
SOFA, points 0.45 (0.02∗) 0.26 (0.19)
APACHE II, points 0.45 (0.02∗) 0.33 (0.09)
IMA: ischemia-modified albumin; CRP: C-reactive protein; SOFA: sequen-
tial organ failure assessment; APACHE: acute physiology and chronic health
evaluation. Data are expressed as simple correlation coefficients (𝑃 values).
∗
𝑃 > 0.05.
A significant positive correlation between IMA and CRP
levels (𝑟 = 0.41, 𝑃 = 0.04) was observed, and their positive
correlation also remained significant (Model 1: 𝛽 = 0.41, 𝑃 =
0.04;Model 2:𝛽 = 0.43,𝑃 = 0.04) in the confounder-adjusted
analyses. However, weak correlations were observed between
CRP and the SOFA and APACHE II scores, as shown in
Table 2.
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Figure 1: Correlation between IMA and SOFA. IMA: ischemia-
modified albumin, SOFA: sequential organ failure assessment. The
SOFA score is log-transformed.
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Figure 2: Correlation between IMA and APACHE II. IMA:
ischemia-modified albumin, APACHE: acute physiology and
chronic health evaluation.TheAPACHE II score is log-transformed.
4. Discussion
The current study demonstrated that the IMA was signif-
icantly and positively correlated with SOFA and APACHE
II sores in preoperative patients awaiting colorectal surgery.
The findings are the first to indicate that serum IMA
measurements can reflect the severity of systemic failure,
as evaluated in the scoring systems, among patients with
colorectal cancers. Since these scores are established and
commonly used in clinical settings [10, 11, 20], the findings
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regarding the IMA appear to be reliable, and the preoperative
IMA levels may help clinicians assess these patients.
Patients with colorectal cancers have pathological abnor-
malities related to oxidative stress [22]. In fact, patients with
several types of cancers can have high IMA levels [23–25].
Hypoxia/ischemia induces IMA by cleavage of the first two
amino acids (Asp-Ala) of the HSA N-terminus, which is
recognized as a strong binding site for transitional metal
ions. [26, 27]. Patients with systemic complications (i.e.,
bacteremia, hepatic, or renal failure) would have enhanced
oxidative stress [3]. These processes offer a possible mecha-
nistic explanation for the correlation between the IMA and
severity scores.
In analyzing the respective components of the SOFA
or APACHE II scores, there was a significant correlation
between the IMA and high heart rate or existing hypotension
(data not shown). These component parameters are possibly
involved in the degree of oxidative stress; accordingly, these
could be particularly important determinants of increased
IMA levels.
In regard to the use of the SOFA and APACHE II
scores, there is some concern that these scoring systems are
complex [13]. On the other hand, the IMA is easily and
inexpensively measurable. Moreover, these scores are not
perfect in predicting postoperative outcomes [13]. IMA levels
have been reported to be predictive of patients’ outcomes
(in particular, short-term outcomes) [28–31], though most
studies examined cardiovascular diseases as outcomes given
the earlier knowledge about IMA [32]. The use of IMA, plus
the SOFAandAPACHE scores, for the assessment of critically
ill patients in association with outcomes, may be a future
issue.
The CRP is a well-known inflammatory marker to
assess patients with critical illnesses [33]. The significance
of CRP measurement in preoperative patient assessment
is recognized to be limited, while, for instance, there was
a report showing the usefulness of CRP in patients with
bacterial infections [33]. Because the CRP is synthesized
in the hepatic cells within 6-to-8 hours after infection [34]
and thereafter the peak of CRP concentrations exists in the
circulation between 36 and 50 hours [35], there may be a gap
between increased serum CRP levels and infectious states.
The production of IMA is induced by the direct stimuli of
oxidative stress, and the serum IMA levels can be increased
immediately within an hour [26]. Thus, the current study
results showing weaker correlations of CRP with SOFA and
APACHE II scores, compared to IMA, are not unexpected.
In comparison with oxidative stress marker IMA, CRP could
not reflect the degree of critical illness severity at the point.
The current study has some limitations. The sample size
was small. The patients were only those awaiting colorectal
surgery and values of APACHE II and SOFA scores revealed
that most of the patients did not have a severe systematic
failure/dysfunction; therefore, careful attention must be paid
when attempting to generalize the current results. The coex-
isting coronary artery disease and ischemic heart disease had
not completely been evaluated in this study. Although the
APACHE II score is generally used in patients treated in
the ICU, its use was extended to the preoperative phase in
the current study. We acknowledge that there may be some
differences relative to the more general use of the score. In
this sense, the current work preliminarily offers a proof of
principle of the validity of IMA in these cases and should
open the way for future studies.
5. Conclusions
In summary, the study results that showed positive corre-
lations between IMA levels and both SOFA and APACHE
II scores suggest that serum IMA can reflect the severity of
systemic failure among patients with colorectal cancers in
the preoperative phase. The easy practicality of the assay will
facilitate future studies looking at the predictive value of IMA
in such patients.
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